These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations. Nandal S; Burt T Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218733 [TBL] [Abstract][Full Text] [Related]
3. Translational -omics: Future potential and current challenges in precision medicine. Wafi A; Mirnezami R Methods; 2018 Dec; 151():3-11. PubMed ID: 29792918 [TBL] [Abstract][Full Text] [Related]
4. Precision medicine for psychopharmacology: a general introduction. Shin C; Han C; Pae CU; Patkar AA Expert Rev Neurother; 2016 Jul; 16(7):831-9. PubMed ID: 27104961 [TBL] [Abstract][Full Text] [Related]
6. The Emerging Role of Proteomics in Precision Medicine: Applications in Neurodegenerative Diseases and Neurotrauma. Alaaeddine R; Fayad M; Nehme E; Bahmad HF; Kobeissy F Adv Exp Med Biol; 2017; 1007():59-70. PubMed ID: 28840552 [TBL] [Abstract][Full Text] [Related]
7. Role of Proteomics in the Development of Personalized Medicine. Jain KK Adv Protein Chem Struct Biol; 2016; 102():41-52. PubMed ID: 26827601 [TBL] [Abstract][Full Text] [Related]
8. Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification. Titz B; Gadaleta RM; Lo Sasso G; Elamin A; Ekroos K; Ivanov NV; Peitsch MC; Hoeng J Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223557 [TBL] [Abstract][Full Text] [Related]
9. The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Olivier M; Asmis R; Hawkins GA; Howard TD; Cox LA Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561483 [TBL] [Abstract][Full Text] [Related]
11. Pharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean. Bafiti V; Katsila T OMICS; 2022 Oct; 26(10):542-551. PubMed ID: 36149303 [TBL] [Abstract][Full Text] [Related]
12. Role of pharmacoproteomics in the development of personalized medicine. Jain KK Pharmacogenomics; 2004 Apr; 5(3):331-6. PubMed ID: 15102547 [TBL] [Abstract][Full Text] [Related]
14. New stationary phases for enrichment and separation in the 'omics' era. Bakry R; Rainer M; Huck CW; Bonn GK Bioanalysis; 2009 Apr; 1(1):151-69. PubMed ID: 21083194 [TBL] [Abstract][Full Text] [Related]
15. Time-Dependent Changes in Urinary Metabolome Before and After Intensive Phase Tuberculosis Therapy: A Pharmacometabolomics Study. Combrink M; du Preez I; Ronacher K; Walzl G; Loots DT OMICS; 2019 Nov; 23(11):560-572. PubMed ID: 31613685 [TBL] [Abstract][Full Text] [Related]
16. Genomic medicine on the frontier of precision medicine. Hasanzad M; Sarhangi N; Naghavi A; Ghavimehr E; Khatami F; Ehsani Chimeh S; Larijani B; Aghaei Meybodi HR J Diabetes Metab Disord; 2022 Jun; 21(1):853-861. PubMed ID: 35673457 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the Early Diagnosis and Prognosis of Cancer. Shukla HD Proteomes; 2017 Oct; 5(4):. PubMed ID: 29068423 [TBL] [Abstract][Full Text] [Related]
18. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Guang MHZ; McCann A; Bianchi G; Zhang L; Dowling P; Bazou D; O'Gorman P; Anderson KC Leuk Lymphoma; 2018 Mar; 59(3):542-561. PubMed ID: 28610537 [TBL] [Abstract][Full Text] [Related]
19. Multiplex assay for multiomics advances in personalized-precision medicine. Popa ML; Albulescu R; Neagu M; Hinescu ME; Tanase C J Immunoassay Immunochem; 2019; 40(1):3-25. PubMed ID: 30632882 [TBL] [Abstract][Full Text] [Related]